Advanced search
Publication Cover
International Medical Case Reports Journal Volume 11, 2018 - Issue
Submit an article Journal homepage
63
Views
9
CrossRef citations to date
0
Altmetric
Case Report

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema

P Singh1 Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany, [email protected]Correspondence[email protected]
,
A Chedid1 Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany, [email protected]
,
SK Deuchler1 Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany, [email protected]
,
T Kohnen2 Ophthalmology University Eye Hospital, Frankfurt am Main, Germany
,
M Müller2 Ophthalmology University Eye Hospital, Frankfurt am Main, Germany
&
FH Koch1 Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany, [email protected]
Pages 265-269 | Published online: 15 Oct 2018

References

  • HernándezCSimó-ServatABogdanovPSimóRDiabetic retinopathy: new therapeutic perspectives based on pathogenic mechanismsJ Endocrinol Invest201740992593528357783
  • QuhillFBeiderbeckACost advantage of fluocinolone acetonide implant (ILUVIEN®) versus ranibizumab in the treatment of chronic diabetic macular oedemaGlob Reg Health Technol Assess201741e155e164
  • BaileyCChakravarthyULoteryAMenonGTalksJMedisoft Audit GroupReal-world experience with 0.2 µg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United KingdomEye201731121707171528737758
  • MathewCYunirakasiwiASanjaySUpdates in the management of diabetic macular edemaJ Diabetes Res2015201579403625984537
  • NguyenQDBrownDMMarcusDMRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology2012119478980122330964
  • EMCILUVIEN 190 micrograms intravitreal implant in applicator – Summary of Product Characteristics (SPC) Available from: https://www.medicines.org.uk/emc/medicine/27636Accessed September 21, 2017
  • CampochiaroPABrownDMPearsonASustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edemaOphthalmology2012119102125213222727177
  • AugustinAJAtorfJThe first European report of real-life clinical outcomes after 3 years of treatment with ILUVIEN® (fluocinolone acetonide) in patients with chronic diabetic macular edema (DME)Invest Ophthalmol Vis Sci2017588928
  • SinghPChedidADeuchlerSKohnenTMuellerMKochFHJThe use of intravitreal implant ILUVIEN® (fluocinolone acetonide) after prior OZURDEX® implant (DEX) (dexamethasone) in patients with diabetic macular edema (DME)-efficacy and safety outcomes from the University Eye Clinic in Frankfurt, GermanyInvest Ophthalmol Vis Sci2017588281828564705
  • GregoriNZFeuerWRosenfeldPJNovel method for analyzing snellen visual acuity measurementsRetina20103071046105020559157
  • HabibMSILUVIEN® technology in the treatment of center-involving diabetic macular edema: a review of the literatureTher Deliv Epub2018626

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.